Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagen...
Guardado en:
Autores principales: | Tatiana Ivanovna Romantsova, Nadezhda Viktorovna Maksimova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/033d27e0f2a149c69bf313f03c494de0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Risk of oncological diseases in patients with diabetes mellitus
por: Gagik Radikovich Galstyan
Publicado: (2009) -
Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013) -
Glibenclamide - profile of efficacy and safety
por: Lyudmila Viktorovna Nedosugova
Publicado: (2011) -
Pharmacoeconomic simulation of delayed results of the treatment of type 2 diabetes mellitus with modern insulin analogsin comparison with oral hypoglycemic agents
por: Ivan Ivanovich Dedov, et al.
Publicado: (2010) -
One-hour postload plasma glucose levels as a new criterion for assessing insulin secretion in obese children
por: O. V. Vasyukova, et al.
Publicado: (2021)